The investigator-initiated study will be conducted at Maimonides Medical Center in Brooklyn, New York, to assess the utility of Lymphoseek in pinpointing lymph nodes most likely to contain cancer.
Open-label study is expected to begin enrollment in 2013 to assess lymph nodes from up to 40 colon cancer subjects.
Navidea president and CEO Mark Pykett said, "This study represents an important step forward in advancing Lymphoseek’s medical and market potential in additional cancers where lymphatic mapping may be very useful but in which effective technologies haven’t been developed."